As the SP-142 antibody showed the greatest clinical benefit in the TNBC, PD-L1+ patient and Ventana PD-L1 (SP142), the IHC assay was the only approved companion diagnostic test for atezolizumab using the tumor-infiltrating IC score with a cut-off of 1% [58,59,60,61]. Here, CD274 is linked to neoplasm.